Form 4 for TRDA Entrada Therapeutics, Inc.
Accepted 2022-03-03 00:00:00 ET · period of report 2022-03-01 · accession 0001104659-22-030005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-03 | 2022-03-01 | TRDA | KREHER NERISSA | Chief Medical Off | A - Grant | $0.00 | +10.3K | 15.5K | +199% | $0 |
| D | 2022-03-03 | 2022-03-01 | TRDA | KREHER NERISSA | Chief Medical Off | A - Grant | $0.00 | +62.1K | 62.1K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-01 | A | A | 10,344 | $0.00 | 15,544 | D | — | — | (F1) Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-03-01 | A | A | 62,063 | $0.00 | 62,063 | D | $11.57 · — to 2032-03-01 | 62,063 Common stock | (F2) 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026. |